Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.37 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.37 |
| ▸ | KAT7 | O95251 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564789 | 1.00 | REN (0.47) | RENGPR119KAT6AKAT5KAT7 | |
| SCHEMBL3564787 | 1.00 | REN (0.47) | RENGPR119KAT6AKAT5KAT7 | |
| SCHEMBL3568207 | 0.90 | REN (0.42) | RENGPR119KAT6AKAT5KAT7 | |
| SCHEMBL3557758 | 0.90 | REN (0.43) | RENGPR119KAT6AKAT5KAT7 | |
| SCHEMBL3557762 | 0.90 | REN (0.43) | RENGPR119KAT6AKAT5KAT7 | |
| SCHEMBL3557756 | 0.90 | REN (0.43) | RENGPR119KAT6AKAT5KAT7 | |
| SCHEMBL3568210 | 0.90 | REN (0.42) | RENGPR119KAT6AKAT5KAT7 | |
| SCHEMBL2850288 | 0.90 | REN (0.49) | RENTP53LMNA | |
| SCHEMBL3568209 | 0.90 | REN (0.42) | RENGPR119KAT6AKAT5KAT7 | |
| SCHEMBL2850285 | 0.90 | REN (0.49) | RENTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-7858624-B2 | Piperidine and morpholine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264432-A1 | Piperidine and Morpholine Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| EP-2010488-A2 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117560-A2 | PIPERIDINE AND MORPHOLINE RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117559-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | REN 1/4885GPR119 720/4885KAT6A 4428/4885 |
| US-20090264432-A1 | Piperidine and Morpholine Renin Inhibitors | REN, ACE, PREP | REN 1/4885GPR119 1165/4885KAT6A 2746/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | REN 1/4885GPR119 478/4885KAT6A 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.